Search

Your search keyword '"Helene Blevi"' showing total 2 results
Start Over Author "Helene Blevi" Publisher elsevier
2 results on '"Helene Blevi"'

1. Low TREM1 expression in whole blood predicts anti-TNF response in inflammatory bowel diseaseResearch in context

Author

Bram Verstockt, Sare Verstockt, Jonas Dehairs, Vera Ballet, Helene Blevi, Willem-Jan Wollants, Christine Breynaert, Gert Van Assche, Séverine Vermeire, and Marc Ferrante

Subjects
Medicine, Medicine (General), R5-920
Abstract

Background: With the changed therapeutic armamentarium for Crohn's disease (CD) and ulcerative colitis (UC), biomarkers predicting treatment response are urgently needed. We studied whole blood and mucosal expression of genes previously reported to predict outcome to anti-TNF therapy, and investigated if the signature was specific for anti-TNF agents. Methods: We prospectively included 54 active IBD patients (24CD, 30UC) initiating anti-TNF therapy, as well as 22 CD patients initiating ustekinumab and 51 patients initiating vedolizumab (25CD, 26UC). Whole blood expression of OSM, TREM1, TNF and TNFR2 was measured prior to start of therapy using qPCR, and mucosal gene expression in inflamed biopsies using RNA-sequencing. Response was defined as endoscopic remission (SES-CD ≤ 2 at week 24 for CD and Mayo endoscopic sub-score ≤ 1 at week 10 for UC). Findings: Baseline whole blood TREM1 was downregulated in future anti-TNF responders, both in UC (FC = 0.53, p = .001) and CD (FC = 0.66, p = .007), as well as in the complete cohort (FC = 0.67, p

Published
2019
Full Text
View/download PDF

2. Low TREM1 expression in whole blood predicts anti-TNF response in inflammatory bowel disease

Author

Bram Verstockt, Willem-Jan Wollants, Vera Ballet, Marc Ferrante, Gert Van Assche, Severine Vermeire, Sare Verstockt, Christine Breynaert, Helene Blevi, and Jonas Dehairs

Subjects
Male, 0301 basic medicine, Research paper, UST, ustekinumab, Gene Expression, VDZ, vedolizumab, TNF, tumour necrosis factor, Inflammatory bowel disease, Gastroenterology, Anti-TNF, AUC, area under the curve, ROC, receiver operator characteristic, 0302 clinical medicine, Crohn Disease, TREM1, LP, lamina propria, Molecular Targeted Therapy, Whole blood, Crohn's disease, IBD, inflammatory bowel disease, Antibodies, Monoclonal, General Medicine, Middle Aged, Prognosis, IFX, infliximab, Ulcerative colitis, 3. Good health, Treatment Outcome, 030220 oncology & carcinogenesis, Biomarker (medicine), Female, ADM, adalimumab, qPCR, real-time polymerase chain reaction, medicine.drug, Adult, medicine.medical_specialty, IBD, General Biochemistry, Genetics and Molecular Biology, Vedolizumab, 03 medical and health sciences, Internal medicine, medicine, Adalimumab, Humans, IQR, interquartile range, Tumor Necrosis Factor-alpha, business.industry, Biomarker, Inflammatory Bowel Diseases, medicine.disease, Triggering Receptor Expressed on Myeloid Cells-1, Infliximab, IL, interleukin, CI, confidence interval, UC, ulcerative colitis, Nomograms, 030104 developmental biology, OSM, oncostatin M, SES-CD, simple endoscopic score for Crohn's disease, CD, Crohn's disease, TNFR2, tumour necrosis factor receptor 2, Colitis, Ulcerative, Personalised medicine, business, Endoscopic remission, Biomarkers, TREM, triggering receptor expressed on myeloid cells
Abstract

BACKGROUND: With the changed therapeutic armamentarium for Crohn's disease (CD) and ulcerative colitis (UC), biomarkers predicting treatment response are urgently needed. We studied whole blood and mucosal expression of genes previously reported to predict outcome to anti-TNF therapy, and investigated if the signature was specific for anti-TNF agents. METHODS: We prospectively included 54 active IBD patients (24CD, 30UC) initiating anti-TNF therapy, as well as 22 CD patients initiating ustekinumab and 51 patients initiating vedolizumab (25CD, 26UC). Whole blood expression of OSM, TREM1, TNF and TNFR2 was measured prior to start of therapy using qPCR, and mucosal gene expression in inflamed biopsies using RNA-sequencing. Response was defined as endoscopic remission (SES-CD ≤ 2 at week 24 for CD and Mayo endoscopic sub-score ≤ 1 at week 10 for UC). FINDINGS: Baseline whole blood TREM1 was downregulated in future anti-TNF responders, both in UC (FC = 0.53, p = .001) and CD (FC = 0.66, p = .007), as well as in the complete cohort (FC = 0.67, p

Published
2019

Catalog

Books, media, physical & digital resources
See catalog results